KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to 98.47%.

  • Pacific Biosciences Of California's EBITDA Margin rose 482800.0% to 98.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 326.54%, marking a year-over-year decrease of 1008000.0%. This contributed to the annual value of 201.05% for FY2024, which is 505700.0% down from last year.
  • Pacific Biosciences Of California's EBITDA Margin amounted to 98.47% in Q3 2025, which was up 482800.0% from 105.73% recorded in Q2 2025.
  • Pacific Biosciences Of California's EBITDA Margin's 5-year high stood at 47.51% during Q3 2021, with a 5-year trough of 1146.92% in Q1 2025.
  • In the last 5 years, Pacific Biosciences Of California's EBITDA Margin had a median value of 195.57% in 2021 and averaged 231.04%.
  • Within the past 5 years, the most significant YoY rise in Pacific Biosciences Of California's EBITDA Margin was 3761400bps (2025), while the steepest drop was -9441300bps (2025).
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's EBITDA Margin stood at 195.57% in 2021, then crashed by -55bps to 303.03% in 2022, then surged by 55bps to 137.02% in 2023, then skyrocketed by 102bps to 3.16% in 2024, then plummeted by -3215bps to 98.47% in 2025.
  • Its EBITDA Margin was 98.47% in Q3 2025, compared to 105.73% in Q2 2025 and 1146.92% in Q1 2025.